Patients With HER2+ Breast Cancer and Brain Metastases Achieve Better OS With Tucatinib Triplet Regimen
A triplet regimen of tucatinib, trastuzumab, and capecitabine helped patients with HER2-positive metastatic breast cancer and brain metastases live longer with reduced disease progression compared with trastuzumab and capecitabine alone.
Adjuvant mFOLFOX6 Increases Hepatectomy Efficacy, Improves DFS in Liver-Only Metastatic CRC
Disease-free survival in liver-only metastatic CRC was significantly improved by introducing adjuvant mFOLFOX6 chemotherapy to hepatectomy
Adding Bevacizumab to Pembrolizumab Enhances Response Rates in Epithelial Ovarian Cancer
The addition of bevacizumab was found to boost responses in patients with epithelial ovarian cancer receiving pembrolizumab.
NBTXR3 Plus Radiotherapy Does Not Negatively Affect Quality of Life in Soft Tissue Sarcoma
An expert from the Institut Curie discusses the risk-benefit ratio associated with NBTXR3 plus radiotherapy for the treatment of patients with soft tissue sarcoma.
COVID-19 Vaccines May Be Less Effective in Patients with Lymphoid Malignancies
Physicians urge patients with lymphoid malignancies to continue precautionary COVID-19 measures regardless of vaccination status.
Oncologists Attribute Pandemic-Related Burnout to Loss of In-Person Patient Interactions
Data presented at the 2021 ASCO Quality Care Symposium demonstrated that in-person interactions had a bigger impact of professional satisfaction than financial stability.
Patients with NETs Can Stop Perioperative Octreotide without Inducing Carcinoid Crisis
New research found that the discontinuation of prophylactic octreotide was not associated with an increased rate or duration of carcinoid crisis in patients with neuroendocrine tumors.
More Research Needed to Determine Biologic Prognostic Factors in Myoepithelial Tumors
More research on the various clinical, pathological, and outcome differences in myoepithelial tumors is needed to offer better prognoses for patients with varying tumor characteristics.
Pediatric Patients With Cancer Experience More Severe Illness After Contracting COVID-19
A greater percentage of children with cancer experienced severe illness and mortality after becoming infected with COVID-19 compared with children in the general pediatric population.
UGN-102 Induces Durable Responses in Patients with Low-Grade Intermediate-Risk NMIBC
Approximately 73% of patients with NMIBC who experienced a complete response after non-surgical primary chemoablation using mitomycin-containing reverse thermal gel UGN-102 remained disease free at 9 months.
Autologous HSCT Continues to Show Sustained Benefit in MCL, But Targeted Therapies May Challenge its Role as Standard Frontline Treatment
Autologous hematopoietic stem-cell transplantation, the standard frontline treatment in treating patients with mantel cell lymphoma, demonstrated superior long-term efficacy compared with interferon alfa in a recent trial.
COVID-19 Vaccine Elicits Similar 6-Month Antibody Response in Both Patients with Solid Tumors and the General Population
The Pfizer-BioNTech COVID-19 vaccine induces similar levels of COVID-19 antibodies in patients with solid cancer compared with people without cancer.
Dostarlimab Elicits Superior Responses in Patients with High Mutational Burden in Endometrial Cancer
Patients with endometrial cancer and high tumor mutational burden experienced superior overall response rates to the agent dostarlimab than patients with low mutational burden.
Vitamin D Intake May Be Protective Against Early-Onset Colorectal Cancer
The data showed that a daily intake of around 300 IU of vitamin D — roughly the same as three 8-oz. glasses of milk — was linked to a nearly 50% decreased risk of early-onset colorectal cancer among women between the ages of 25 and 42 years.
CheckMate-73L To Explore Ipilimumab and Nivolumab Combo in Non-Small Cell Lung Cancer Treatment
The ongoing CheckMate-73L trial seeks to determine if nivolumab plus ipilimumab following nivolumab plus chemoradiation could become the new standard of care in treating non-small cell lung cancer, says Nagla F. Abdel Karim, MD.
New Research Aims to Incorporate PARP Inhibitors in Lung Cancer Treatment
Researchers are using biomarker-testing to determine which patients with lung cancer might benefit from PARP inhibitors.
Blood-Based Tests Should Be Included in Single-Cancer Screenings
Multicancer early detection tests provided specified and accurate cancer signal origin detection across more than 50 tumor types.
Brain Imaging Guidelines Needed for Patients with Metastatic Kidney Cancer
New data emphasizes need for routine brain imaging in patients with advanced or metastatic renal cell carcinoma with prior treatment and high metastatic burden.
Nomogram May Have the Power to Predict Treatment Outcomes in Patients with Prostate Cancer Subtype
Telaglenastat Plus Cabozantinib Fails to Improve PFS in Metastatic RCC, But Still Holds Promise
The results of the phase 2 CANTATA trial indicate that the combination of telaglenastat/cabozantinib does not significantly improve PFS, however, telaglenastat might still prove effective in certain populations.
Ultralow Risk 70-Gene Promises Superior Survival Outcomes in Patients with Early-Stage Breast Cancer
Regardless of clinical risk, the survival prognosis of patients with early-stage breast cancer is high amongst those who have ultralow risk disease indicated by a 70-gene signature.
Patients with Relapsed/Refractory B-ALL Achieve Long-Term Clinical Benefit with KTE-X19
A virtual presentation at the 2021 American Society of Clinical Oncology Annual Meeting suggested that patients with B-ALL benefit from single infusions of KTE-X19 (Tecartus).
Patient Characteristics Linked to Time on Treatment and Survival in Patients With mCRC Receiving Cetuximab
KRAS mutational status and geographical region were associated with time on treatment (TOT), and body mass index (BMI) and age were linked with overall survival (OS) in patients with metastatic colorectal cancer mCRC) being treated with second-line cetuximab (Erbitux) after irinotecan or oxaliplatin-based regimens.
Olaparib Is Beneficial 1 Year After Standard of Care Therapies in BRCA, High-Risk, Early HER2- Breast Cancer
Patients with BRCA1/2-mutant, early HER2-negative breast cancer at a high risk of recurrence saw a clinically meaningful benefit 1 year after standard of care when treated with olaparib.
Adding Frontline Brentuximab Vedotin in Pediatric High-Risk Hodgkin Lymphoma Treatment Improves Outcomes
Adding the antibody-drug conjugate to the frontline treatment of patients with pediatric high-risk Hodgkin lymphoma resulted in favorable clinical outcomes.
TIL Therapy May Be the Curative Answer for Metastatic Melanoma
Tumor-infiltrating lymphocytes show great promise in the metastatic melanoma space, but questions remain.
Genetic Changes Linked to Increased CRC Risk
Immunotherapy Regimen Continues to Improve GI Treatment
With immunotherapy options expanding for patients with a range of gastrointestinal cancers to include combination strategies with chemotherapy, their use in the treatment course should come sooner rather than later for those with high PD-L1 expression.
Chronic Immune-Related Adverse Events Are Common in Certain Melanoma Subgroups
Chronic immune-related adverse effects arising from adjuvant anti–PD-1 therapy in patients with high-risk melanoma are more common than previously recognized, and often persisted with longer follow-up.
Lurbinectedin Shows Promise in Small Cell Lung Cancer Treatment
Wade T. Iams, MD, discusses the efficacy and safety of lurbinectedin in patients with small cell lung cancer, the impact of its approval on the paradigm, and remaining questions regarding its use.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
2 Clarke Drive Cranbury, NJ 08512